[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

622.P1.62 622. Non-Hodgkin Lymphoma - Biology, excluding Therapy: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 10, 2011: 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)
Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

Christine Damm-Welk, PhD1*, Lara Mussolin, PhD2*, Marta Pillon, MD2*, Martin Zimmermann, PhD1*, Alfred Reiter, MD1, Wilhelm Woessmann, MD1* and Angelo Rosolen, MD2*

1Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany
2Pediatric Hematology and Oncology, University of Padova, Padova, Italy

Mesenchymal Stromal Cells Orchestrate Follicular Lymphoma Cell Niche Through the CCL2-Dependent Recruitment and Polarization of Monocytes

Fabien Guilloton1*, Gersende Caron1,2*, Cédric Ménard1,3*, Céline Pangault, PharmD, PhD1,3*, Patricia Amé-Thomas1*, Joelle Dulong4*, John De Vos5*, Delphine Rossille, PhD6*, Thierry Lamy, MD, PhD1,7, Thierry Fest8* and Karin Tarte3,9*

1INSERM U917, Rennes, France
2CHU Rennes, RENNES, France
3CHU Rennes, Rennes, France
4EFS Bretagne, Rennes, France
5U1040, Montpellier, France
6INSERM U936, Rennes, France
7Hematology Dept, CHU, Rennes, France
8Pôle Biologie, CHU Rennes, Rennes, France
9INSERM U917 Faculté de médecine, Rennes, France, Rennes, France

Hairy Cell Leukaemia Displaying Multiple Surface Immunoglobulin Isotypes Reveal a Functional B-Cell Receptor In Which Isotype Roles Differ

Nicola J Weston-Bell, PhD1*, Gavin Babbage1*, Francesco Forconi2*, Hanneke C. Kluin-Nelemans3 and Surinder S Sahota, PhD1*

1Cancer Sciences Division, School of Medicine, University of Southampton, Southampton, United Kingdom
2Ematologia e Trapianti, Università di Siena - AOUS, Siena, Italy
3Hematology, University Medical Centre Groningen, Groningen, Netherlands

Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Ranjana H. Advani, MD1, Fangxin Hong, PhD2*, Hailun Li, MS2*, Brad S. Kahl, MD3, Michael Pfreundschuh4 and Marita Ziepert5*

1Med/Oncology, Stanford Unversity Medical Center, Stanford, CA
2Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA
3Department of Medicine-Hematology/Oncology, University of Wisconsin, Madison, WI
4University of Saarland, Homburg, Germany
5Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig

  c-MYC Drives PBK Expression in High-Grade Malignant Lymphomas Through E2F1

Fang Hu1*, Xianfeng Zhao, MD, PhD2, Hongbin Fang, PhD3*, Ronald Gartenhaus1*, Poss Elise Daniela2* and Aaron P. Rapoport, MD4

1Medicine, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Baltimore, MD
2University of Maryland School of Medicine, Baltimore, MD
3Biostatistics, University of Maryland School of Medicine, Baltimore, MD
4Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD

Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression 

Anne J. Novak, Ph.D.1, Takashi Akasaka, MD, PhD2, Michelle K Manske1*, Esteban Braggio, PhD3, Tammy Price-Troska1*, Steve Ziesmer1*, Secreto Frank, Ph.D.4*, Rafael Fonseca, MD5, Mamta Gupta, PhD6, Mark E Law7*, Thomas E. Witzig, MD1, Martin JS Dyer, MA, DPhil, FRCP, FRCPath2*, Ahmet Dogan7, Ellen McPhail, MD8, James R Cerhan, MD, PhD9 and Stephen Ansell1*

1Division of Hematology, Mayo Clinic, Rochester, MN
2MRC Toxicology Unit, Leicester University, Leicester, United Kingdom
3Division of Hematology - Oncology, Mayo Clinic Arizona, Scottsdale, AZ
4Division of Hematology, Mayo Clinic
5Mayo Clinic Scottsdale, Scottsdale, AZ
6Clinic, Mayo
7Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
8Anatomic Pathology & Hematology, Mayo Clinic, Rochester, MN
9Department of Health Sciences Research, Mayo Clinic, Rochester, MN

Rituximab Activation of AKT and HIF Pathways Is Dependent on Membrane Lipid Raft Cholesterol Levels in Lymphoma Cells

Yumi Nozaki, MD1*, Toru Mitsumori, MD1*, Norio Komatsu, M.D., Ph.D.2 and Keita Kirito, MD1

1Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan
2Department of Hematology, Juntendo University School of Medicine, Bunkyo-ku, Japan

Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience

Brian L. Burnette, MD1, Gregory Wiseman, MD2*, Thomas M. Habermann, MD3, William R Macon, MD4*, Stephen M. Ansell, MD, PhD3, David James Inwards, MD5, Ivana N. Micallef, MD6, Patrick B. Johnston6, Kay M. Ristow3*, Thomas E. Witzig, MD6 and Grzegorz S. Nowakowski, MD3

1Hematology, Mayo Clinic Foundation, Rochester, MN
2Mayo Clinic, Rochester, MN
3Division of Hematology, Mayo Clinic, Rochester, MN
4College of Medicine, Mayo Clinic, Rochester, MN
5Department of Medicine/Division of Hematology, Mayo Clinic, Rochester, MN
6Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Distinct Human and Viral Interleukin-6 Profiles and Other Viral and Immunologic Abnormalities In KSHV-Associated Multicentric Castleman Disease: Relationship with Disease Activity and Individual Disease Manifestations

Mark N Polizzotto, MBBS, BMedSc1, Thomas S Uldrick, MD, MS1, Victoria Wang, PhD1*, Karen Aleman, RN1*, Kathleen M Wyvill, RN1*, Vickie Marshall, PhD2*, Stefania Pittaluga, MD, PhD3, Deirdre O'Mahony, MBBS1*, Denise Whitby, PhD2*, Giovanna Tosato, PhD4*, Seth M. Steinberg, PhD5*, Richard F Little, MD, MPH1 and Robert Yarchoan, MD1*

1HIV/AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
2Viral Oncology Section, AIDS and Cancer Virus Program, SAIC-Frederick, National Cancer Institute Frederick, Frederick, MD
3Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD
4Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD
5Biostatistics and Data Management Section, National Institutes of Health, National Cancer Institute, Rockville, MD

Primary Intraocular Lymphomas Display A Remarkably Biased Immunoglobulin Heavy Chain Gene Repertoire and Precisely Targeted Somatic Hypermutation Suggesting Antigenic Selection of the Neoplastic Cells

Nabila Belhouachi1*, Evangelia Stalika2*, Bahram Bodaghi3*, Myriam Boudjoghra1*, Nathalie Cassoux3*, Christine Fardeau3*, Sylvie Baudet1*, Phuc Le Hoang3*, Helene Merle-Beral1, Kostas Stamatopoulos, MD2 and Frederic Davi1*

1Laboratory of Hematology, Hopital Pitie-Salpetriere , Paris, France
2Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
3Department of Ophtalmology, Hopital Pitie-Salpetriere , Paris, France

Serum Soluble Tumor Necrosis Factor Recepter 2 Levels Is Associated with the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Regimen

Nobuhiko Nakamura, MD1*, Naoe Goto, MD, PhD2,3*, Hisashi Tsurumi, MD, PhD1, Masao Takemura, PhD4*, Nobuhiro Kanemura, MD, PhD1, Takeshi Hara, MD, PhD1, Senji Kasahara, Md, PhD1, Mitsuru Seishima, Prof.4*, Tsuyoshi Takami, Prof.5* and Hisataka Moriwaki, Prof.6*

1First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan
2First Department of Internal Medicine , Gifu University Graduate School of Medicine, Gifu , Japan
3Department of Immunopathology, Gifu University Graduate School of Medicine, Gifu, Japan
4Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Gifu, Japan
5Department of Immunopathology, Gifu University Graduate School of Medicine, Gifu, Japan
6First Department of Internal Medicine, Gifu University Graduate School of Medicine

Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

Irit Avivi, MD1*, Ariel Zilberlicht, MD2*, Eldad J Dann, MD1, Jacob M. Rowe, MD1, Ronit Leiba, MSc.3*, Tal Faibish, MSc2* and Rachel Bar-Shalom, MD4*

1Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
2Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel
3Biostatistics Unit, Rambam Medical Center, Haifa, Israel
4Nuclear Medicine, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

Follicular Lymphoma with Diffuse Large B-Cell Component At Initial Diagnosis Appears to Be Associated with a Loss of BCL2 Translocation and Inferior Progression Free Survival

Kevin Tay, MD1, Yee Siang Shew, MBBS1*, Yu Lin Gao1*, Whee Sze Ong2*, Tiffany Tang, MBBS, MRCP1*, Richard Quek, MBBS, MRCP1*, Daryl Tan, MBBS, MRCP3, Leonard Tan, MBBS, MRCPath4*, Miriam Tao, MBBS, MRCP1*, Soo Yong Tan, MBBS, MRCPath4* and Soon Thye Lim, MBBS, MRCP1*

1Department of Medical Oncology, National Cancer Center Singapore, SG, Singapore
2Department of Biostatistics, National Cancer Center Singapore, SG, Singapore
3Department of Hematology, Singapore General Hospital, SG, Singapore
4Department of Pathology, Singapore General Hospital, SG, Singapore

Impact of Occult Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Hiroshi Arima, MD1*, Hayato Maruoka2*, Koji Nasu2*, Yuki Funayama, MD1*, June Takeda, MD1*, Nobuhiko Yamauchi, MD1*, Kazunari Aoki, MD1*, Aiko Kato, MD1*, Yuichiro Ono, MD1*, Seiji Nagano, MD1*, Yoko Takiuchi, MD1*, Sumie Tabata, MD, PhD1*, Akiko Matsushita, MD1*, Yukihiro Imai, MD, PhD3*, Takayuki Takahashi, MD, PhD4* and Takayuki Ishikawa, MD, PhD1*

1Department of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Kobe, Japan
2Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan
3Department of Clinical Pathology, Kobe City Medical Center General Hospital, Kobe, Japan
4Department of Hematology and Oncology, Shinko Hospital, Kobe, Japan

Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation

Sarah C. Rutherford, MD1*, Wayne Tam, MD, PhD2, Richard R. Furman, MD1, Rebecca Elstrom, MD1, Jia Ruan, MD, PhD1, Morton Coleman, MD1*, John P. Leonard, MD1 and Peter Martin, MD1

1Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY
2Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY

Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment – a Single Institution Experience

Jason M. Jones, MD1*, Thomas M. Habermann, MD1, Kay M. Ristow1*, Paul Kurtin, MD2, Ellen McPhail, MD2, Carrie A. Thompson, MD1*, Joseph P. Colgan, MD1*, Luis F. Porrata, MD1, Svetomir N. Markovic, MD, PhD1, Thomas E. Witzig, MD1, James A. Martenson Jr., MD3* and Grzegorz S. Nowakowski, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Anatomic Pathology & Hematology, Mayo Clinic, Rochester, MN
3Department of Radiation Oncology, Mayo Clinic, Rochester, MN

Serum Soluble LR11 As a Novel Biomarker for B Cell Lymphoma

Takeharu Kawaguchi, M.D.1*, Chikako Ohwada, MD, PhD.1, Morihiro Higashi, M.D., PhD.2*, Masahiro Takeuchi, MD, PhD1*, Shio Sakai, M.D., PhD.1*, Yusuke Takeda, M.D., PhD.1*, Naomi Shimizu, MD, PhD1*, Emiko Sakaida, M.D., PhD.1*, Kohei Takubo, PhD.3*, Hiroyuki Ebinuma, PhD.3*, Isamu Fukamachi, PhD.3*, Jun-Ichi Tamaru, M.D., PhD.2*, Koutaro Yokote, MD, PhD4*, Hideaki Bujo, MD, PhD5* and Chiaki Nakaseko, MD, PhD1

1Department of Hematology, Chiba University Hospital, Chiba, Japan
2Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
3Tsukuba Research Institute, Sekisui Medical Co Ltd, Tsukuba, Japan
4Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
5Department of Genome Research and Clinical Application, Chiba University Graduate School of Medicine, Chiba, Japan

A Prognostic Index for Acute and Lymphoma Type Adult T-Cell Leukemia/LymphomaClinically Relevant Abstract

Hiroo Katsuya1*, Takeharu Yamanaka2*, Kenji Ishitsuka, MD, PhD1, Atae Utsunomiya, MD3, Hidenori Sasaki1*, Shuichi Hanada4, Tetsuya Eto, MD5*, Yukiyoshi Moriuchi, MD6*, Yoshio Saburi7*, Masaharu Miyahara8*, Eisaburo Sueoka, MD, PhD9*, Naokuni Uike, MD, PhD10*, Shinichiro Yoshida, MD, PhD11*, Kiyoshi Yamashita12*, Kunihiro Tsukasaki, MD, PhD13, Hitoshi Suzushima14*, Yuju Ohno15*, Hitoshi Matsuoka16*, Tatsuro Jo17*, Junji Suzumiya, MD, PhD18 and Kazuo Tamura, MD, PhD1*

1The Department of medicine, Division of Medical Oncology, Hematology, and Infectious Diseases, Fukuoka University, Fukuoka, Japan
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center
3Dept. of Hematology, Imamura Bun-in Hospital
4Department of Hematology, Kagoshima Medical Center
5Hematology, Hamanomachi Hospital, Fukuoka
6Department of Hematology, Sasebo City General Hospital, Sasebo, Japan
7Department of Hematology, Oita Prefectural Hospital
8Department of Internal Medicine, Karatsu Red Cross Hospital
9Department of Transfusion Medicine, Saga University Hospital, Saga, Japan
10Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
11Department of Hematology, Nagasaki Medical Center, Ohmura, Japan
12Department of Internal Medicine, Miyazaki Prefectural Hospital
13Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences
14Department of Hematology, NTT West Kyushu Hospital
15Department of Internal Medicine, Kitakyushu Municipal Medical Center
16Department of Internal Medicine, Koga General Hospital
17Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital
18Shimane University, Cancer Center, Izumo, Japan

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Carlos Montalban, MD, PhD1, Victor Abraira, PhD2*, Luca Arcaini3*, Eva Domingo-Domenech, MD4*, Pablo Guisado-Vasco, MD, PhD5*, Emilio Iannitto, MD6, Manuela Mollejo, MD7*, Estella Matutes8, Andrés JM Ferreri, MD9, Antonio Salar, MD, PhD10*, Andrea Carpaneto, MD11*, Ricardo Pérez, MD12*, Jose Luis Bello13*, Miguel Hernandez14*, Dolores Caballero, MD15* and Miguel A. Piris, MD, PhD16*

1Dept. of Int. Med., Hospital Ramon y Cajal, Madrid, Spain
2Clinical Bioestatistics Unit. IRYCIS., Hospital Ramon y Cajal, Madrid, Spain
3Divisions of Hematology, University of Pavia Medical School, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
4Hematology, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain
5Internal Medicine, Hospital Ramon y Cajal, Madrid, Spain
6 UO of Hematology and BMT, Department of Oncology, San Giuseppe Moscati Hospital, Taranto, Italy
7Hospital Virgen de la Salud, Toledo, Spain
8Section of Haemato-Oncology, The Royal Marsden Hospital, London SW3 6JJ, United Kingdom
9Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milano, Italy
10Hematology Department, Hospital del Mar, Barcelona, Spain
11UOC Ematologia, Ospedale Sant'Anna, Ronciglione, Viterbo, Italy
12Oncology, Hospital Gregorio Marañon, Madrid, Spain
13Hematology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
14Hematology, Hospital Universitario de Canarias, Tenerife, Spain
15Hematology, Hospital Universitario Salamanca, Salamanca, Spain
16Pathology , Hospital Marques de Valdecilla, Santander, Spain

Burkitt Lymphoma Specific Zinc Finger Protein ZNF385B Is Involved in Regulation of B Cell Apoptosis

Kazutoshi Iijima, PhD1*, Hiroyuki Yamada, MD2*, Masashi Miharu, MD3*, Atsuko Nakazawa, MD, PhD4*, Junichiro Fujimoto, MD, PhD5, Kenichiro Kobayashi, MD, PhD6*, Hajime Okita, MD, PhD7* and Nobutaka Kiyokawa, MD, PhD7*

1Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan
2 Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development
3Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development
4Department of Pathology, National Medical Center for Children and Mothers
5Clinical Research Center, National Center for Child Health and Development
6National Research Institute for Child Health and Development, Department of Pediatric Hematology and Oncology Research
7Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Colm Keane, MB BCh BAO MSc MRCPI FRCPath1,2*, Linda Shen, FRCPA3*, Erica Han4*, Jamie P Nourse, PhD5*, Rod Lea, PhD6*, Peter Mollee, MBBS, FRCPA, FRACP, MMSc7, Devinder S Gill, MD8 and Maher K Gandhi, PhD, FRACP, FRCPath, FRCP5

1Haematology, Princess Alexandra Hospital, Brisbane, Australia
2Clinical Immunohaematology, Queensland Institute of Medical Research, Brisbane, Australia
3Pathology, Princess Alexandra Hospital, Brisbane, Australia
4Queensland Institute of Medical Research, Brisbane, Australia
5Dept. of Clinical Immunohaematology, Queensland Institute of Medical Research, Brisbane, Australia
6Griffith Genomics Centre, Griffith University, , Gold Coast, Australia
7Dept. of Haematology, Princess Alexandra Hospital, Brisbane, Australia
8Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia

TGF-β Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL)

Zhi-Zhang Yang, MD, Deanna Grote*, Steven C. Ziesmer*, Thomas E. Witzig, MD, Anne J. Novak, Ph.D. and Stephen M. Ansell, MD, PhD

Division of Hematology, Mayo Clinic, Rochester, MN

Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL):  A Children’s Oncology Group Report

Mitchell S. Cairo, MD1,2,3,4,5, Nancy Day, Ph.D.6*, Stanton Goldman, MD7*, Warren G. Sanger, PhD8, Lauren Harrison, RN, MSN1*, Megan S. Lim, MD, PhD9, Rodney R. Miles, MD, PhD10 and Sherrie L. Perkins, MD, PhD10

1Pediatrics, New York Medical College, Valhalla, NY
2Medicine, New York Medical College, Valhalla, NY
3Pathology, New York Medical College, Valhalla, NY
4Microbiology & Immunology, New York Medical College, Valhalla, NY
5Cell Biology & Anatomy, New York Medical College, Valhalla, NY
6Pediatrics, Columbia University Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY
7Medical City Children's Hospital, Dallas, TX
8Human Genetics Lab, University of Nebraska, Medical Center, Omaha, NE
9Department of Pathology, The University of Michigan, Ann Arbor, MI
10Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT

Innmune-Related Risk Factors for Non-Hodgkin Lymphoma in Twins

Jun Wang, M.D.1*, Thomas M Mack, M.D., M.P.H.2*, Amie Hwang, M.P.H.1*, Bharat N. Nathwani, M.D.3*, Ann Hamilton, Ph.D.1* and Wendy Cozen, DO, MPH4

1Preventive Medicine, Univ of Southern California Norris Cancer Ctr, Los Angeles, CA
2Preventive Medicine and Pathology, Univ. of Southern California Norris Cancer Ctr., Los Angeles, CA
3Pathology Department, Cedars Sinai Medical Center, Los Angeles
4Preventive Medicine, University of Southern California, Los Angeles, CA

HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study

Michael Furman, MD1*, Pascual Balsalobre2*, Brady E Beltran, MD3*, Michele Bibas, MD4, Mark Bower, MD5*, Weina Chen, MD, PhD6, Silvia Montoto, MD7, Roberto N Miranda, MD8, Nahid M. Nanaji, MD, MPH9, Jose-Tomas Navarro, MD10*, Adam C. Seegmiller, MD, PhD11*, Julie M Vose, MD12 and Jorge J Castillo, MD13

1The Miriam Hospital, Providence, RI
2Hospital General Universitario Gregorio Marañon, Hematology , Madrid, Spain
3Oncology/Radiotherapy, Edgardo Rebagliati Martins Hospital, Lima, Peru
4Clinical Department - Hematology., National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS., Rome, Italy
5Medical Oncology, Chelsea & Westminster Hospital, London, United Kingdom
6Ameripath North Texas, Dallas, TX
7Centre for Haemato-Oncology, Barts Cancer Institute, QMUL, London, United Kingdom
8Hematopathology Unit 072, M.D. Anderson Cancer Center, Houston, TX
9Pathology, University of Maryland Medical Center, Baltimore, MD
10Pathology, Hospital Germans Trias i Pujol, Barcelona, Spain
11Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN
12Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE
13Hematology and Oncology, The Miriam Hospital, Providence, RI

B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship

Anuj K. Mahindra, MD1, Aliyah R. Sohani, MD2, Christiana E. Toomey1*, James S. Michaelson, PhD2*, Jeffrey A. Barnes, MD, PhD1, Jeremy S. Abramson, MD3, Ronald Takvorian, MD4*, Noopur S. Raje, MD5 and Ephraim P. Hochberg, MD1

1Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA
2Department of Pathology, Massachusetts General Hospital, Boston, MA
3Cancer Center, Center for Lymphoma, Massachusetts General Hospital, Boston, MA
4Massachusetts General Hospital Cancer Center, Boston, MA
5Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma

Matthew J Maurer, MS1*, James R Cerhan, MD, PhD2, Jerry A Katzmann, PhD3*, Ahmet Dogan, M.D., Ph.D.4, Mamta Gupta, Ph.D5, William R Macon, MD6*, Sergei I Syrbu, MD7*, Brian K Link, MD8, Ivana N. Micallef, MD9 and Thomas E Witzig4

1Health Sciences Research, Mayo Clinic, Rochester, MN
2Department of Health Sciences Research, Mayo Clinic, Rochester, MN
3Dept. of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN
4Mayo Clinic, Rochester, MN
5Hematology, Mayo Clinic, Rochester, MN
6College of Medicine, Mayo Clinic, Rochester, MN
7University of Iowa, Iowa City, IA
8University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA
9Division of Hematology, Mayo Clinic, Rochester, MN

Prognostic Impact of Clinical and Tumor Associated Variables in a Population-Based Cohort of Mantle Cell Lymphomas in the Stockholm Region Between 1998-2010

Stefanie Baumgartner Wennerholm, MD1*, Monika Klimkowska, MD., Ph.D.2*, Lina Nygren, MD3*, Eva Kimby, M.D., Ph.D. 4 and Birgitta Sander, MD, Ph.D.5

1Center for Hematology, Karolinska University Hospital, Stockholm, Sweden
2Pathology, Karolinska University Hospital, Stockholm, Sweden
3Oto-Rhino-Laryngology, Karolinska University Hospital, Stockholm, Sweden
4Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden
5Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

Chiara Lobetti-Bodoni, MD1,2*, Paola MV Rancoita, PhD3,4*, Silvia Montoto, MD5, Armando Lopez-Guillermo, MD6, Annarita Conconi, MD7, Rita Coutinho, MD8*, Janet Matthews5*, Silvia Franceschetti, MD7*, Francesco Bertoni, MD1, Franco Cavalli, MD1, Michele Ghielmini, MD1, Andrew Lister, MD9*, Emili Montserrat, MD8 and Emanuele Zucca, MD1

1Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
2Division of Hematology, Department of Experimental Medicine and Oncology, University of Torino, A.O.U. San Giovanni Battista, Torino, Italy
3Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland
4Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
5Centre for Haemato-Oncology, Barts Cancer Institute, QMUL, London, United Kingdom
6Department of Hematology, Hospital Clínic, Barcelona, Spain
7Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
8Department of Hematology, Hospital Clinic, Barcelona, Spain
9Dept. of Medical Oncology, St. Bartholomew’s Hospital, London, United Kingdom

Prognositc Inpact of Tumor-Infiltrating Cells Especially CD163 Positive Macrophage in DLBCL Treated with R-CHOP

Naoe Goto, MD, PhD1,2*, Nobuhiro Kanemura, MD, PhD3, Hisashi Tsurumi, MD, PhD3, Nobuhiko Nakamura, MD3*, Senji Kasahara, MD, PhD3, Takeshi Hara, MD, PhD3, Hisataka Moriwaki, Prof.3* and Tsuyoshi Takami, Prof.2*

1 First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan
2Department of Immunopathology, Gifu University Graduate School of Medicine, Gifu, Japan
3First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan

Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort Study

Hyun Ae Jung1*, Seok Jin Kim, MD, PhD2, Jun Ho Jang, MD, PhD1*, Kihyun Kim, MD3, Chul Won Jung4 and Won Seog Kim5*

1Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
2Medicine, Samsung Med. Ctr., Seoul, South Korea
3Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Division of Hematology-Oncology , Seoul, South Korea
4Medicine, Samsung Medical Center, Seoul, South Korea
5Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea

Lymphoproliferative Disorder and Acquired C1-INH Deficiency. A Case Series of 48 Patients

Fabrizio Foieni, MD1*, Andrea Zanichelli, MD1*, Anna Coerezza, MD1*, Roberto Castelli, MD2*, Lorena Maggioni, PhD1*, Chiara Suffritti, PhD1*, Erika Bonanni1*, Augusto B. Federici, MD3 and Marco Cicardi, MD1*

1Dipartimento di Scienze Cliniche Luigi Sacco, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
2Department of Internal Medicine, University of Milan, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy
3Department of Internal Medicine, University of Milan, Milano, Italy

Usefulness of Positron Emission Tomography Using 18F-FDG Performed At Diagnosis and During Initial Chemotherapy for Imaging Primary Central Nervous System Lymphoma: A 24 Immunocompetent patient’s Study.  Clinically Relevant Abstract

Herve Ghesquieres, MD, PhD1*, Céline Ferlay2*, Bertrand Richioud, MD3*, Vanina Isnardi, MD4*, Emmanuelle Nicolas-Virlizier, MD5*, Izabela-Irina Domnisoru, MD6*, Philippe Rey, MD6*, François Ducray, MD7*, Jérome Honnorat, MD, PhD8*, Emmanuel Jouanneau, MD, PhD9*, Marie Pierre Sunyach, MD10*, Pierre Biron, MD6*, Catherine Sebban, MD6*, Jean-Yves Blay, MD, PhD5 and Sébastien Cimarelli, MD4*

1Hematology, Centre Léon Bérard, UMR 5239 CNRS, Lyon, France
2Biostatistics, Centre Léon Berard, Lyon, France
3Radiology, Centre Léon Berard, Lyon, France
4Nuclear Medicine, Centre Léon Bérard, Lyon, France
5Hematology, Centre Léon Bérard, Lyon, France
6Onco-Hematology, Centre Léon Bérard, Lyon, France
7Neurology , Hospices Civils de Lyon , Bron , France
8Neurology, Hospices Civils de Lyon , Bron , France
9Neurosurgery , Hospices Civils de Lyon , Bron , France
10Radiotherapy , Centre Léon Bérard, Lyon, France

Clinical Significance of Serum Concentration of L-Kynurenine for T-Cell Lymphoma Treated with CHOP

Nobuhiro Kanemura, MD, PhD, Hisashi Tsurumi, MD, PhD, Junji Nagano, MD*, Takeshi Hara, MD, PhD, Kengo Ogawa, MD*, Soranobu Ninomiya, MD*, Naoe Goto, MD, PhD*, Senji Kasahara, MD, PhD and Hisataka Moriwaki, Prof.*

First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan

Herpes Zoster Is Associated with An Increased Risk of Subsequent Lymphoid Malignancies — A Population-Based Matched-Control Study in Taiwan

Yi-Chang Liu, MD1,2,3*, Yi-Hsin Yang, PhD4*, Hui-Hua Hsiao, MD1,2*, Ming-Yu Yang, PhD5,6*, Wen-Chi Yang, MD6* and Sheng-Fung Lin, MD2,6

1Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan
2Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
4Statistical Analysis Laboratory, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
5Graduate Institute of Clinical Medical Sciences, Kaohsiung Division, Chang Gung University, Kaohsiung, Taiwan
6Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Correlation of Fc Gamma RIIA Polymorphisms with EBV-Positivity and LMP1 Expression in Patients with Low Grade B-Cell Lymphomas

Panagiotis Theodorou Diamantopoulos1*, Vassiliki Kalotychou1*, Athanassios Galanopoulos2*, Nikolaos Spanakis3*, Katerina Polonyfi1*, Georgia Diamantopoulou4*, Efthymia Bazanis1*, Marina Siakantaris, M.D.1*, Theodoros Vassilakopoulos1*, Maria K. Angelopoulou5*, Eleni Variami1*, Nikolaos Anagnostopoulos2*, Ioannis Rombos1*, Konstantinos Konstantopoulos1*, Panagoula Kollia6*, Gerasimos Pangalis7*, John Meletis1* and Nora-Athina Viniou1

11st Department of Internal Medicine, Hematology Unit, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
2Department of Clinical Hematology, “G. Gennimatas” District General Hospital, Athens, Greece
33Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
4Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
5Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
6Faculty of Biology, School of Physical Sciences, National and Kapodistrian University of Athens, Athens, Greece
7National and Kapodistrian University of Athens, Athens, Greece

*signifies non-member of ASH